Transforming Outcomes for Patients with Chronic Respiratory Disease
ProterixBio is developing chronic care platforms to improve patient outcomes, starting with pulmonary diseases. As a key part of these programs, ProterixBio will provide actionable biological measurements in order to improve patient assessment and enhance treatment decisions, solving critical unmet needs.
An initial focus is early leading to late COPD (chronic obstructive pulmonary disease), a progressive disease which causes reduced air flow in the lungs, leading to significant morbidity and mortality. The ultimate goal is to reduce the frequency and severity of exacerbations, slow progression, lower morbidity and mortality, and lower the overall cost of the disease.
ProterixBio is working with world renown advisors to ensure the development of clinically useful tests which have a clear and compelling effect on patient outcomes when combined with disease modifying treatments and/or care.
Enhancing Treatment Decisions To Improve Outcomes